In the phase I/II ECHO-202/KEYNOTE-037 study of epacadostat plus pembrolizumab in patients with advanced tumors, promising responses were observed in melanoma (ORR 60.5%) and NSCLC with PD-L1 tumor proportion score (TPS) < 50% (ORR 24.4%), and treatment was generally well tolerated [17]. Here, CD274 is linked to neoplasm.